Loading...
•
Dec 31, 2021
VYNE Q4 2021 Earnings Report
Reported year-end financial results and provided a corporate update.
Key Takeaways
VYNE Therapeutics reported financial results for the fourth quarter and year ended December 31, 2021. The company focused on developing novel therapies for immuno-inflammatory conditions and completed the divestiture of their topical minocycline MST franchise.
Completed the divestiture of topical minocycline MST franchise in January.
Reported positive Phase 1b safety data for FMX114.
Released promising preclinical data for InhiBET inhibitor platform.
Plan to report Phase 2a safety and efficacy results in the second quarter.
Forward Guidance
VYNE plans to report Phase 2a safety and efficacy results in the second quarter, initiate their first in-human clinical study for VYN201 in the second half of the year, followed by exercising of the option and an IND filing for VYN202.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...